search
Back to results

Cost-effectiveness of Forced Aerobic Exercise for Stroke Rehabilitation

Primary Purpose

Stroke, Cerebrovascular Disorders, Brain Diseases

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Aerobic Exercise
Upper Extremity Repetitive Task Practice
Sponsored by
The Cleveland Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Stroke focused on measuring stroke, aerobic exercise, forced exercise, repetitive task practice, arm function, upper extremity

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. ≥ 6 months following single ischemic or hemorrhagic stroke confirmed with neuroimaging,
  2. Fugl-Meyer motor score 19-55 in the involved upper extremity,
  3. Ambulatory ≥ 20 meters with no more than contact guard assistance, and
  4. 18-85 years of age.

Exclusion Criteria:

  1. hospitalization for myocardial infarction, heart failure or heart surgery within 3 months,
  2. cardiac arrhythmia,
  3. hypertrophic cardiomyopathy,
  4. severe aortic stenosis,
  5. pulmonary embolus,
  6. significant contractures,
  7. anti-spasticity injection within 3 months of enrollment and
  8. other contraindication to exercise

Sites / Locations

  • Cleveland Clinic Main Campus

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Aerobic Exercise & Repetitive Task Practice

Upper Extremity Repetitive Task Practice Only

Arm Description

Participants will perform the following: 45 minutes of cycling 45 minutes of upper extremity repetitive arm exercises

Participants will perform the following: 1. 90 minutes of upper extremity repetitive arm exercises

Outcomes

Primary Outcome Measures

Fugl-Meyer Assessment (FMA)
This is a 33 item assessment of post-stroke upper extremity impairment. Total score is reported, scores range from 0-66, with higher scores indicating a better outcome.
Fugl-Meyer Assessment (FMA)
This is a 33 item assessment of post-stroke upper extremity impairment. Total score is reported, scores range from 0-66, with higher scores indicating a better outcome.
Fugl-Meyer Assessment (FMA)
This is a 33 item assessment of post-stroke upper extremity impairment. Total score is reported, scores range from 0-66, with higher scores indicating a better outcome.
Fugl-Meyer Assessment (FMA)
This is a 33 item assessment of post-stroke upper extremity impairment. Total score is reported, scores range from 0-66, with higher scores indicating a better outcome.
Fugl-Meyer Assessment (FMA)
This is a 33 item assessment of post-stroke upper extremity impairment. Total score is reported, scores range from 0-66, with higher scores indicating a better outcome.
Fugl-Meyer Assessment (FMA)
This is a 33 item assessment of post-stroke upper extremity impairment. Total score is reported, scores range from 0-66, with higher scores indicating a better outcome.
Action Research Arm Test (ARAT)
This is an assessment of post-stroke upper extremity function. Total score is reported, scores range from 0-57, with higher scores indicating a better outcome.
Action Research Arm Test (ARAT)
This is an assessment of post-stroke upper extremity function. Total score is reported, scores range from 0-57, with higher scores indicating a better outcome.
Action Research Arm Test (ARAT)
This is an assessment of post-stroke upper extremity function. Total score is reported, scores range from 0-57, with higher scores indicating a better outcome.
Action Research Arm Test (ARAT)
This is an assessment of post-stroke upper extremity function. Total score is reported, scores range from 0-57, with higher scores indicating a better outcome.
Action Research Arm Test (ARAT)
This is an assessment of post-stroke upper extremity function. Total score is reported, scores range from 0-57, with higher scores indicating a better outcome.

Secondary Outcome Measures

Wolf Motor Function Test (WMFT)
This consists of 2 strength tasks and 15 timed tasks of both the affected upper extremity and the unaffected upper extremity. Total Functional Ability Score is reported, scores range from 0-75, with higher scores indicating a better outcome.
Wolf Motor Function Test (WMFT)
This consists of 2 strength tasks and 15 timed tasks of both the affected upper extremity and the unaffected upper extremity. Total Functional Ability Score is reported, scores range from 0-75, with higher scores indicating a better outcome.
Stroke Impact Scale (SIS)
This is a self-reported questionnaire evaluating quality of life. Normalized Hand Function is reported, scores range from 0-100, with higher scores indicating a better outcome.
Stroke Impact Scale (SIS)
This is a self-reported questionnaire evaluating quality of life. Normalized Hand Function is reported, scores range from 0-100, with higher scores indicating a better outcome.
Stroke Impact Scale (SIS)
This is a self-reported questionnaire evaluating quality of life. Normalized Hand Function is reported, scores range from 0-100, with higher scores indicating a better outcome.
Stroke Impact Scale (SIS)
This is a self-reported questionnaire evaluating quality of life. Normalized Hand Function is reported, scores range from 0-100, with higher scores indicating a better outcome.
Patient-Reported Outcomes Measurement Information System (PROMIS-29)
A self-reported questionnaire evaluating physical, mental, and social health. T-scores are reported separately for Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities, Physical Function, and Pain Interference. A score of 40 is one standard deviation lower than the mean of the reference population. A score of 60 is one standard deviation higher than the mean of the reference population. For PROMIS measures, higher scores equals more of the concept being measured (e.g., more Fatigue, more Physical Function). Thus a score of 60 is one standard deviation above the average referenced population. This could be a desirable or undesirable outcome, depending upon the concept being measured.
Patient-Reported Outcomes Measurement Information System (PROMIS-29)
A self-reported questionnaire evaluating physical, mental, and social health. T-scores are reported separately for Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities, Physical Function, and Pain Interference. A score of 40 is one standard deviation lower than the mean of the reference population. A score of 60 is one standard deviation higher than the mean of the reference population. For PROMIS measures, higher scores equals more of the concept being measured (e.g., more Fatigue, more Physical Function). Thus a score of 60 is one standard deviation above the average referenced population. This could be a desirable or undesirable outcome, depending upon the concept being measured.
Patient-Reported Outcomes Measurement Information System (PROMIS-29)
A self-reported questionnaire evaluating physical, mental, and social health. T-scores are reported separately for Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities, Physical Function, and Pain Interference. A score of 40 is one standard deviation lower than the mean of the reference population. A score of 60 is one standard deviation higher than the mean of the reference population. For PROMIS measures, higher scores equals more of the concept being measured (e.g., more Fatigue, more Physical Function). Thus a score of 60 is one standard deviation above the average referenced population. This could be a desirable or undesirable outcome, depending upon the concept being measured.
Patient-Reported Outcomes Measurement Information System (PROMIS-29)
A self-reported questionnaire evaluating physical, mental, and social health. T-scores are reported separately for Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities, Physical Function, and Pain Interference. A score of 40 is one standard deviation lower than the mean of the reference population. A score of 60 is one standard deviation higher than the mean of the reference population. For PROMIS measures, higher scores equals more of the concept being measured (e.g., more Fatigue, more Physical Function). Thus a score of 60 is one standard deviation above the average referenced population. This could be a desirable or undesirable outcome, depending upon the concept being measured.
Center for Epidemiological Studies-Depression (CES-D)
This is a 20 item assessment of depressive symptomology. Total score is reported, scores range from 0-60, with higher scores indicating higher risk of depression.
Center for Epidemiological Studies-Depression (CES-D)
This is a 20 item assessment of depressive symptomology. Total score is reported, scores range from 0-60, with higher scores indicating higher risk of depression.
Center for Epidemiological Studies-Depression (CES-D)
This is a 20 item assessment of depressive symptomology. Total score is reported, scores range from 0-60, with higher scores indicating higher risk of depression.
Center for Epidemiological Studies-Depression (CES-D)
This is a 20 item assessment of depressive symptomology. Total score is reported, scores range from 0-60, with higher scores indicating higher risk of depression.
Six-Minute Walk Test (6MWT)
Total distance (feet) traveled over a 6 minute period.
Six-Minute Walk Test (6MWT)
Total distance (feet) traveled over a 6 minute period.
Six-Minute Walk Test (6MWT)
Total distance (feet) traveled over a 6 minute period.
Six-Minute Walk Test (6MWT)
Total distance (feet) traveled over a 6 minute period.
Six-Minute Walk Test (6MWT)
Total distance (feet) traveled over a 6 minute period.
Modified Rankin Scale
0-6 scale to determine degree of disability in individuals with a disabling condition. A score of 0 indicates no symptoms, 1 indicates no significant disability despite symptoms, 2 indicates slight disability, 3 indicates moderate disability, 4 indicates moderately severe level of disability, 5 indicates severe disability, and 6 indicates death.
Modified Rankin Scale
0-6 scale to determine degree of disability in individuals with a disabling condition. A score of 0 indicates no symptoms, 1 indicates no significant disability despite symptoms, 2 indicates slight disability, 3 indicates moderate disability, 4 indicates moderately severe level of disability, 5 indicates severe disability, and 6 indicates death.
Modified Rankin Scale
0-6 scale to determine degree of disability in individuals with a disabling condition. A score of 0 indicates no symptoms, 1 indicates no significant disability despite symptoms, 2 indicates slight disability, 3 indicates moderate disability, 4 indicates moderately severe level of disability, 5 indicates severe disability, and 6 indicates death.
Modified Rankin Scale
0-6 scale to determine degree of disability in individuals with a disabling condition. A score of 0 indicates no symptoms, 1 indicates no significant disability despite symptoms, 2 indicates slight disability, 3 indicates moderate disability, 4 indicates moderately severe level of disability, 5 indicates severe disability, and 6 indicates death.
Right Step Length
Mean right step length (cm) across two 2-minute walking trials
Right Step Length
Mean right step length (cm) across two 2-minute walking trials
Left Step Length
Mean left step length (cm) across two 2-minute walking trials
Left Step Length
Mean left step length (cm) across two 2-minute walking trials
Right Step Width
Mean right step width (cm) across two 2-minute walking trials
Right Step Width
Mean right step width (cm) across two 2-minute walking trials
Left Step Width
Mean left step width (cm) across two 2-minute walking trials
Left Step Width
Mean left step width (cm) across two 2-minute walking trials
Right Stance Time
Mean time (in seconds) spent in stance phase on the right lower extremity across two 2-minute walking trials
Right Stance Time
Mean time (in seconds) spent in stance phase on the right lower extremity across two 2-minute walking trials
Left Stance Time
Mean time (in seconds) spent in stance phase on the left lower extremity across two 2-minute walking trials
Left Stance Time
Mean time (in seconds) spent in stance phase on the left lower extremity across two 2-minute walking trials
Right Swing Time
Mean time (in seconds) spent in swing phase on the right lower extremity across two 2-minute walking trials
Right Swing Time
Mean time (in seconds) spent in swing phase on the right lower extremity across two 2-minute walking trials
Left Swing Time
Mean time (in seconds) spent in swing phase on the left lower extremity across two 2-minute walking trials
Left Swing Time
Mean time (in seconds) spent in swing phase on the left lower extremity across two 2-minute walking trials
Walking Speed
Mean m/s across two 2-minute walking trials
Walking Speed
Mean m/s across two 2-minute walking trials
Walking Cadence
Mean steps/minute across two 2-minute walking trials
Walking Cadence
Mean steps/minute across two 2-minute walking trials
Left Knee Range of Motion
Mean peak degree of left knee flexion across two 2-minute walking trials
Left Knee Range of Motion
Mean peak degree of left knee flexion across two 2-minute walking trials
Right Knee Range of Motion
Mean peak degree of right knee flexion across two 2-minute walking trials
Right Knee Range of Motion
Mean peak degree of right knee flexion across two 2-minute walking trials
Left Ankle Range of Motion
Mean peak degree of left ankle dorsiflexion across two 2-minute walking trials
Left Ankle Range of Motion
Mean peak degree of left ankle dorsiflexion across two 2-minute walking trials
Right Ankle Range of Motion
Mean peak degree of right ankle dorsiflexion across two 2-minute walking trials
Right Ankle Range of Motion
Mean peak degree of right ankle dorsiflexion across two 2-minute walking trials
Left Hip Range of Motion (sagittal plane)
Mean peak degree of left hip flexion across two 2-minute walking trials
Left Hip Range of Motion (sagittal plane)
Mean peak degree of left hip flexion across two 2-minute walking trials
Right Hip Range of Motion (sagittal plane)
Mean peak degree of right hip flexion across two 2-minute walking trials
Right Hip Range of Motion (sagittal plane)
Mean peak degree of right hip flexion across two 2-minute walking trials
Left Hip Range of Motion (coronal plane)
Mean peak degree of left hip abduction across two 2-minute walking trials
Left Hip Range of Motion (coronal plane)
Mean peak degree of left hip abduction across two 2-minute walking trials
Right Hip Range of Motion (coronal plane)
Mean peak degree of right hip abduction across two 2-minute walking trials
Right Hip Range of Motion (coronal plane)
Mean peak degree of right hip abduction across two 2-minute walking trials
Left Hip Range of Motion (transverse plane)
Mean peak degree of left hip external rotation across two 2-minute walking trials
Left Hip Range of Motion (transverse plane)
Mean peak degree of left hip external rotation across two 2-minute walking trials
Right Hip Range of Motion (transverse plane)
Mean peak degree of right hip external rotation across two 2-minute walking trials
Right Hip Range of Motion (transverse plane)
Mean peak degree of right hip external rotation across two 2-minute walking trials

Full Information

First Posted
January 17, 2019
Last Updated
April 25, 2023
Sponsor
The Cleveland Clinic
search

1. Study Identification

Unique Protocol Identification Number
NCT03819764
Brief Title
Cost-effectiveness of Forced Aerobic Exercise for Stroke Rehabilitation
Official Title
Cost-effectiveness and Efficacy of a Combined Intervention to Facilitate Motor Recovery Following Stroke
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
April 11, 2019 (Actual)
Primary Completion Date
August 2023 (Anticipated)
Study Completion Date
August 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The Cleveland Clinic

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The purpose of this study is to investigate whether aerobic exercise improves the participant's ability to recover function in the arm and leg affected by the participant's stroke. The investigators are also calculating the cost effectiveness of the rehabilitation interventions.
Detailed Description
The aims of the study are to determine the clinical efficacy and cost-effectiveness of combining aerobic exercise training with upper extremity motor task practice to improve motor recovery following stroke. It is hypothesized that the neurophysiologic impact of aerobic exercise may augment motor recovery associated with motor task practice. To test this hypothesize, 60 individuals with chronic stroke will be recruited to participate in this randomized clinical trial. Following screening and informed consent, all participants will undergo an exercise stress test to determine response to maximal exertion. Following the stress test, baseline clinical assessments will be obtained to quantify upper extremity function, gait, endurance, and self-reported quality of life. Additionally, variables to determine degree of disability will be obtained. Individuals will be randomized to one of two interventions: 45 min of forced-rate aerobic exercise paired with 45 min of upper limb repetitive task practice or two back-to-back 45-minute sessions of upper limb repetitive task practice. The interventions will occur 3 times per week for 8 weeks. Outcomes assessing motor function and disability will be repeated at mid-treatment, end of treatment, and at 4 weeks, 6-months and 12-months following end of treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke, Cerebrovascular Disorders, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Vascular Diseases, Cardiovascular Diseases
Keywords
stroke, aerobic exercise, forced exercise, repetitive task practice, arm function, upper extremity

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Aerobic Exercise & Repetitive Task Practice
Arm Type
Active Comparator
Arm Description
Participants will perform the following: 45 minutes of cycling 45 minutes of upper extremity repetitive arm exercises
Arm Title
Upper Extremity Repetitive Task Practice Only
Arm Type
Active Comparator
Arm Description
Participants will perform the following: 1. 90 minutes of upper extremity repetitive arm exercises
Intervention Type
Behavioral
Intervention Name(s)
Aerobic Exercise
Intervention Description
Cycling on a recumbent stationary bike with a specialized motor that forces the individual to cycle approximately 30-35% faster than your self-selected speed
Intervention Type
Behavioral
Intervention Name(s)
Upper Extremity Repetitive Task Practice
Intervention Description
Repetitive arm exercises
Primary Outcome Measure Information:
Title
Fugl-Meyer Assessment (FMA)
Description
This is a 33 item assessment of post-stroke upper extremity impairment. Total score is reported, scores range from 0-66, with higher scores indicating a better outcome.
Time Frame
Baseline
Title
Fugl-Meyer Assessment (FMA)
Description
This is a 33 item assessment of post-stroke upper extremity impairment. Total score is reported, scores range from 0-66, with higher scores indicating a better outcome.
Time Frame
midpoint (4 weeks from Baseline)
Title
Fugl-Meyer Assessment (FMA)
Description
This is a 33 item assessment of post-stroke upper extremity impairment. Total score is reported, scores range from 0-66, with higher scores indicating a better outcome.
Time Frame
end of treatment (8 weeks from Baseline)
Title
Fugl-Meyer Assessment (FMA)
Description
This is a 33 item assessment of post-stroke upper extremity impairment. Total score is reported, scores range from 0-66, with higher scores indicating a better outcome.
Time Frame
end of treatment +4 weeks (12 weeks from Baseline)
Title
Fugl-Meyer Assessment (FMA)
Description
This is a 33 item assessment of post-stroke upper extremity impairment. Total score is reported, scores range from 0-66, with higher scores indicating a better outcome.
Time Frame
end of treatment +6 months (8 months from Baseline)
Title
Fugl-Meyer Assessment (FMA)
Description
This is a 33 item assessment of post-stroke upper extremity impairment. Total score is reported, scores range from 0-66, with higher scores indicating a better outcome.
Time Frame
end of treatment +1 year (14 months from Baseline)
Title
Action Research Arm Test (ARAT)
Description
This is an assessment of post-stroke upper extremity function. Total score is reported, scores range from 0-57, with higher scores indicating a better outcome.
Time Frame
Baseline
Title
Action Research Arm Test (ARAT)
Description
This is an assessment of post-stroke upper extremity function. Total score is reported, scores range from 0-57, with higher scores indicating a better outcome.
Time Frame
end of treatment (8 weeks from Baseline)
Title
Action Research Arm Test (ARAT)
Description
This is an assessment of post-stroke upper extremity function. Total score is reported, scores range from 0-57, with higher scores indicating a better outcome.
Time Frame
end of treatment +4 weeks (12 weeks from Baseline)
Title
Action Research Arm Test (ARAT)
Description
This is an assessment of post-stroke upper extremity function. Total score is reported, scores range from 0-57, with higher scores indicating a better outcome.
Time Frame
end of treatment +6 months (8 months from Baseline)
Title
Action Research Arm Test (ARAT)
Description
This is an assessment of post-stroke upper extremity function. Total score is reported, scores range from 0-57, with higher scores indicating a better outcome.
Time Frame
end of treatment +1 year (14 months from Baseline)
Secondary Outcome Measure Information:
Title
Wolf Motor Function Test (WMFT)
Description
This consists of 2 strength tasks and 15 timed tasks of both the affected upper extremity and the unaffected upper extremity. Total Functional Ability Score is reported, scores range from 0-75, with higher scores indicating a better outcome.
Time Frame
Baseline
Title
Wolf Motor Function Test (WMFT)
Description
This consists of 2 strength tasks and 15 timed tasks of both the affected upper extremity and the unaffected upper extremity. Total Functional Ability Score is reported, scores range from 0-75, with higher scores indicating a better outcome.
Time Frame
end of treatment (8 weeks from Baseline)
Title
Stroke Impact Scale (SIS)
Description
This is a self-reported questionnaire evaluating quality of life. Normalized Hand Function is reported, scores range from 0-100, with higher scores indicating a better outcome.
Time Frame
Baseline
Title
Stroke Impact Scale (SIS)
Description
This is a self-reported questionnaire evaluating quality of life. Normalized Hand Function is reported, scores range from 0-100, with higher scores indicating a better outcome.
Time Frame
end of treatment (8 weeks from Baseline)
Title
Stroke Impact Scale (SIS)
Description
This is a self-reported questionnaire evaluating quality of life. Normalized Hand Function is reported, scores range from 0-100, with higher scores indicating a better outcome.
Time Frame
end of treatment +6 months (8 months from Baseline)
Title
Stroke Impact Scale (SIS)
Description
This is a self-reported questionnaire evaluating quality of life. Normalized Hand Function is reported, scores range from 0-100, with higher scores indicating a better outcome.
Time Frame
end of treatment +1 year (14 months from Baseline)
Title
Patient-Reported Outcomes Measurement Information System (PROMIS-29)
Description
A self-reported questionnaire evaluating physical, mental, and social health. T-scores are reported separately for Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities, Physical Function, and Pain Interference. A score of 40 is one standard deviation lower than the mean of the reference population. A score of 60 is one standard deviation higher than the mean of the reference population. For PROMIS measures, higher scores equals more of the concept being measured (e.g., more Fatigue, more Physical Function). Thus a score of 60 is one standard deviation above the average referenced population. This could be a desirable or undesirable outcome, depending upon the concept being measured.
Time Frame
Baseline
Title
Patient-Reported Outcomes Measurement Information System (PROMIS-29)
Description
A self-reported questionnaire evaluating physical, mental, and social health. T-scores are reported separately for Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities, Physical Function, and Pain Interference. A score of 40 is one standard deviation lower than the mean of the reference population. A score of 60 is one standard deviation higher than the mean of the reference population. For PROMIS measures, higher scores equals more of the concept being measured (e.g., more Fatigue, more Physical Function). Thus a score of 60 is one standard deviation above the average referenced population. This could be a desirable or undesirable outcome, depending upon the concept being measured.
Time Frame
end of treatment (8 weeks from Baseline)
Title
Patient-Reported Outcomes Measurement Information System (PROMIS-29)
Description
A self-reported questionnaire evaluating physical, mental, and social health. T-scores are reported separately for Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities, Physical Function, and Pain Interference. A score of 40 is one standard deviation lower than the mean of the reference population. A score of 60 is one standard deviation higher than the mean of the reference population. For PROMIS measures, higher scores equals more of the concept being measured (e.g., more Fatigue, more Physical Function). Thus a score of 60 is one standard deviation above the average referenced population. This could be a desirable or undesirable outcome, depending upon the concept being measured.
Time Frame
end of treatment +6 months (8 months from Baseline)
Title
Patient-Reported Outcomes Measurement Information System (PROMIS-29)
Description
A self-reported questionnaire evaluating physical, mental, and social health. T-scores are reported separately for Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities, Physical Function, and Pain Interference. A score of 40 is one standard deviation lower than the mean of the reference population. A score of 60 is one standard deviation higher than the mean of the reference population. For PROMIS measures, higher scores equals more of the concept being measured (e.g., more Fatigue, more Physical Function). Thus a score of 60 is one standard deviation above the average referenced population. This could be a desirable or undesirable outcome, depending upon the concept being measured.
Time Frame
end of treatment +1 year (14 months from Baseline)
Title
Center for Epidemiological Studies-Depression (CES-D)
Description
This is a 20 item assessment of depressive symptomology. Total score is reported, scores range from 0-60, with higher scores indicating higher risk of depression.
Time Frame
Baseline
Title
Center for Epidemiological Studies-Depression (CES-D)
Description
This is a 20 item assessment of depressive symptomology. Total score is reported, scores range from 0-60, with higher scores indicating higher risk of depression.
Time Frame
end of treatment (8 weeks from Baseline)
Title
Center for Epidemiological Studies-Depression (CES-D)
Description
This is a 20 item assessment of depressive symptomology. Total score is reported, scores range from 0-60, with higher scores indicating higher risk of depression.
Time Frame
end of treatment +6 months (8 months from Baseline)
Title
Center for Epidemiological Studies-Depression (CES-D)
Description
This is a 20 item assessment of depressive symptomology. Total score is reported, scores range from 0-60, with higher scores indicating higher risk of depression.
Time Frame
end of treatment +1 year (14 months from Baseline)
Title
Six-Minute Walk Test (6MWT)
Description
Total distance (feet) traveled over a 6 minute period.
Time Frame
Baseline
Title
Six-Minute Walk Test (6MWT)
Description
Total distance (feet) traveled over a 6 minute period.
Time Frame
end of treatment (8 weeks)
Title
Six-Minute Walk Test (6MWT)
Description
Total distance (feet) traveled over a 6 minute period.
Time Frame
end of treatment +4 weeks (12 weeks from Baseline)
Title
Six-Minute Walk Test (6MWT)
Description
Total distance (feet) traveled over a 6 minute period.
Time Frame
end of treatment +6 months (8 months from Baseline)
Title
Six-Minute Walk Test (6MWT)
Description
Total distance (feet) traveled over a 6 minute period.
Time Frame
end of treatment +1 year (14 months from Baseline)
Title
Modified Rankin Scale
Description
0-6 scale to determine degree of disability in individuals with a disabling condition. A score of 0 indicates no symptoms, 1 indicates no significant disability despite symptoms, 2 indicates slight disability, 3 indicates moderate disability, 4 indicates moderately severe level of disability, 5 indicates severe disability, and 6 indicates death.
Time Frame
Baseline
Title
Modified Rankin Scale
Description
0-6 scale to determine degree of disability in individuals with a disabling condition. A score of 0 indicates no symptoms, 1 indicates no significant disability despite symptoms, 2 indicates slight disability, 3 indicates moderate disability, 4 indicates moderately severe level of disability, 5 indicates severe disability, and 6 indicates death.
Time Frame
end of treatment (8 weeks from Baseline)
Title
Modified Rankin Scale
Description
0-6 scale to determine degree of disability in individuals with a disabling condition. A score of 0 indicates no symptoms, 1 indicates no significant disability despite symptoms, 2 indicates slight disability, 3 indicates moderate disability, 4 indicates moderately severe level of disability, 5 indicates severe disability, and 6 indicates death.
Time Frame
end of treatment +6 months (8 months from Baseline)
Title
Modified Rankin Scale
Description
0-6 scale to determine degree of disability in individuals with a disabling condition. A score of 0 indicates no symptoms, 1 indicates no significant disability despite symptoms, 2 indicates slight disability, 3 indicates moderate disability, 4 indicates moderately severe level of disability, 5 indicates severe disability, and 6 indicates death.
Time Frame
end of treatment +1 year (14 months from Baseline)
Title
Right Step Length
Description
Mean right step length (cm) across two 2-minute walking trials
Time Frame
Baseline
Title
Right Step Length
Description
Mean right step length (cm) across two 2-minute walking trials
Time Frame
end of treatment (8 weeks from Baseline)
Title
Left Step Length
Description
Mean left step length (cm) across two 2-minute walking trials
Time Frame
Baseline
Title
Left Step Length
Description
Mean left step length (cm) across two 2-minute walking trials
Time Frame
end of treatment (8 weeks from Baseline)
Title
Right Step Width
Description
Mean right step width (cm) across two 2-minute walking trials
Time Frame
Baseline
Title
Right Step Width
Description
Mean right step width (cm) across two 2-minute walking trials
Time Frame
end of treatment (8 weeks from Baseline)
Title
Left Step Width
Description
Mean left step width (cm) across two 2-minute walking trials
Time Frame
Baseline
Title
Left Step Width
Description
Mean left step width (cm) across two 2-minute walking trials
Time Frame
end of treatment (8 weeks from Baseline)
Title
Right Stance Time
Description
Mean time (in seconds) spent in stance phase on the right lower extremity across two 2-minute walking trials
Time Frame
Baseline
Title
Right Stance Time
Description
Mean time (in seconds) spent in stance phase on the right lower extremity across two 2-minute walking trials
Time Frame
end of treatment (8 weeks from Baseline)
Title
Left Stance Time
Description
Mean time (in seconds) spent in stance phase on the left lower extremity across two 2-minute walking trials
Time Frame
Baseline
Title
Left Stance Time
Description
Mean time (in seconds) spent in stance phase on the left lower extremity across two 2-minute walking trials
Time Frame
end of treatment (8 weeks from Baseline)
Title
Right Swing Time
Description
Mean time (in seconds) spent in swing phase on the right lower extremity across two 2-minute walking trials
Time Frame
Baseline
Title
Right Swing Time
Description
Mean time (in seconds) spent in swing phase on the right lower extremity across two 2-minute walking trials
Time Frame
end of treatment (8 weeks from Baseline)
Title
Left Swing Time
Description
Mean time (in seconds) spent in swing phase on the left lower extremity across two 2-minute walking trials
Time Frame
Baseline
Title
Left Swing Time
Description
Mean time (in seconds) spent in swing phase on the left lower extremity across two 2-minute walking trials
Time Frame
end of treatment (8 weeks from Baseline)
Title
Walking Speed
Description
Mean m/s across two 2-minute walking trials
Time Frame
Baseline
Title
Walking Speed
Description
Mean m/s across two 2-minute walking trials
Time Frame
end of treatment (8 weeks from Baseline)
Title
Walking Cadence
Description
Mean steps/minute across two 2-minute walking trials
Time Frame
Baseline
Title
Walking Cadence
Description
Mean steps/minute across two 2-minute walking trials
Time Frame
end of treatment (8 weeks from Baseline)
Title
Left Knee Range of Motion
Description
Mean peak degree of left knee flexion across two 2-minute walking trials
Time Frame
Baseline
Title
Left Knee Range of Motion
Description
Mean peak degree of left knee flexion across two 2-minute walking trials
Time Frame
end of treatment (8 weeks from Baseline)
Title
Right Knee Range of Motion
Description
Mean peak degree of right knee flexion across two 2-minute walking trials
Time Frame
Baseline
Title
Right Knee Range of Motion
Description
Mean peak degree of right knee flexion across two 2-minute walking trials
Time Frame
end of treatment (8 weeks from Baseline)
Title
Left Ankle Range of Motion
Description
Mean peak degree of left ankle dorsiflexion across two 2-minute walking trials
Time Frame
Baseline
Title
Left Ankle Range of Motion
Description
Mean peak degree of left ankle dorsiflexion across two 2-minute walking trials
Time Frame
end of treatment (8 weeks from Baseline)
Title
Right Ankle Range of Motion
Description
Mean peak degree of right ankle dorsiflexion across two 2-minute walking trials
Time Frame
Baseline
Title
Right Ankle Range of Motion
Description
Mean peak degree of right ankle dorsiflexion across two 2-minute walking trials
Time Frame
end of treatment (8 weeks from Baseline)
Title
Left Hip Range of Motion (sagittal plane)
Description
Mean peak degree of left hip flexion across two 2-minute walking trials
Time Frame
Baseline
Title
Left Hip Range of Motion (sagittal plane)
Description
Mean peak degree of left hip flexion across two 2-minute walking trials
Time Frame
end of treatment (8 weeks from Baseline)
Title
Right Hip Range of Motion (sagittal plane)
Description
Mean peak degree of right hip flexion across two 2-minute walking trials
Time Frame
Baseline
Title
Right Hip Range of Motion (sagittal plane)
Description
Mean peak degree of right hip flexion across two 2-minute walking trials
Time Frame
end of treatment (8 weeks from Baseline)
Title
Left Hip Range of Motion (coronal plane)
Description
Mean peak degree of left hip abduction across two 2-minute walking trials
Time Frame
Baseline
Title
Left Hip Range of Motion (coronal plane)
Description
Mean peak degree of left hip abduction across two 2-minute walking trials
Time Frame
end of treatment (8 weeks from Baseline)
Title
Right Hip Range of Motion (coronal plane)
Description
Mean peak degree of right hip abduction across two 2-minute walking trials
Time Frame
Baseline
Title
Right Hip Range of Motion (coronal plane)
Description
Mean peak degree of right hip abduction across two 2-minute walking trials
Time Frame
end of treatment (8 weeks from Baseline)
Title
Left Hip Range of Motion (transverse plane)
Description
Mean peak degree of left hip external rotation across two 2-minute walking trials
Time Frame
Baseline
Title
Left Hip Range of Motion (transverse plane)
Description
Mean peak degree of left hip external rotation across two 2-minute walking trials
Time Frame
end of treatment (8 weeks from Baseline)
Title
Right Hip Range of Motion (transverse plane)
Description
Mean peak degree of right hip external rotation across two 2-minute walking trials
Time Frame
Baseline
Title
Right Hip Range of Motion (transverse plane)
Description
Mean peak degree of right hip external rotation across two 2-minute walking trials
Time Frame
end of treatment (8 weeks from Baseline)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: ≥ 6 months following single ischemic or hemorrhagic stroke confirmed with neuroimaging, Fugl-Meyer motor score 19-55 in the involved upper extremity, Ambulatory ≥ 20 meters with no more than contact guard assistance, and 18-85 years of age. Exclusion Criteria: hospitalization for myocardial infarction, heart failure or heart surgery within 3 months, cardiac arrhythmia, hypertrophic cardiomyopathy, severe aortic stenosis, pulmonary embolus, significant contractures, anti-spasticity injection within 3 months of enrollment and other contraindication to exercise
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Susan Linder, DPT
Organizational Affiliation
The Cleveland Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cleveland Clinic Main Campus
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Cost-effectiveness of Forced Aerobic Exercise for Stroke Rehabilitation

We'll reach out to this number within 24 hrs